Belanoff
Principal executive officer pay for Belanoff, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
CORCEPT THERAPEUTICS INC (CORT) FY2020–FY2025
Lagged peersTSR -38% vs peer group -5% over FY2020–FY2025
Paid for declineCAP $13,607,297→$14,755,842 while $100 invested went $216.00→$133.00 (FY2020–FY2025)
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2020 | $5.8M | $13.6M |
| FY2021 | $11.0M | $4.3M |
| FY2022 | $7.4M | $9.6M |
| FY2023 | $9.3M | $15.8M |
| FY2024 | $9.9M | $22.8M |
| FY2025 | $15.3M | $14.8M |
The company's "$100 invested" index ran $216.00 at FY2020 → $133.00 by FY2025 — an annualized return of -9.2%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: -9.2%/yr at CORT ( FY2020–FY2025). See the CEO track-record ranking for context.